NCT00501683已完成1 期
A Mass Balance Study to Investigate the Metabolic Disposition of a 400 mg Single, Oral Dose of GSK189075 in Healthy Male Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 2
- 主要终点
- Laboratory tests to determine the amount of radiolabelled drug that is found in blood, urine, and feces. Blood samples at Days 1-5.
研究概览
简要总结
This study will look at the relative amounts of GSK189075 that are found in samples of blood, urine, and feces of healthy male volunteers. Results of the study will be used to understand how the drug is converted in the body and how it is eliminated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Are a healthy, non-smoking male.
- •Are 30 to 55 years old, inclusive.
- •Have a Body Mass Index (BMI) between 19-30 kg/m2, inclusive; and a body weight >110 lbs.
- •Have a history of regular bowel movements (at least 4 times per week).
- •Are willing and able to provide written informed consent before the start of any study-related procedures.
排除标准
- •Have any significant laboratory abnormality or history of liver or kidney disease.
- •Have any significant abnormality in your electrocardiograms (ECG) which are recordings of your heart rhythm.
- •Have a current condition(s) that alters normal gastrointestinal (GI) function (such as constipation or removal of your gallbladder).
- •Have an illness that requires treatment by a physician in the 30 days before screening or a fever and illness in the 5 days before dosing.
- •Have blood pressure that is outside the normal range.
- •Have a resting pulse rate that is outside the normal range.
- •Have had surgery within 3 months before screening, unless approved by the GSK medical monitor.
- •Have a drug allergy which the investigator feels would make it unsafe for you to participate in the study.
- •Have a history of or current abuse of alcohol.
- •Have a history of or current use of illicit drugs, or a positive drug screen.
- •Have used tobacco products within 3 months prior to screening or have a positive cotinine test result.
- •Are unable to refrain from foods or beverages containing coffee, tea, or chocolate for 72 hours before dosing with study drug and until 24 hours after dose.
- •Have a positive test for human immunodeficiency virus (HIV) antibody or hepatitis B surface antigen or hepatitis C antibody.
- •Have taken prescription or non-prescription drugs, including vitamins, herbal products, or plant-derived supplements (including St John's Wort) within 14 days (or less than 5 half-lives) before the first dose of study medication, unless approved by the GSK medical monitor
- •Have participated in an investigational drug study within the 30 days before screening, or participated within the last 12 months in a study with another radio labeled drug product.
- •Have a total radiation exposure from the previous 3-year period that is over 10 mSv (either from your work or through participation in other research studies). Clinical (therapeutic or diagnostic) exposure will not be included.
- •Have donated blood (450 mL or more) within the previous 12 weeks.
- •Are in an occupation which requires monitoring for radiation exposure, nuclear medicine procedures or have had excessive x-rays within the past 12 months.
- •Are not able to follow the study directions.
结局指标
主要结局
Laboratory tests to determine the amount of radiolabelled drug that is found in blood, urine, and feces. Blood samples at Days 1-5.
时间窗: at Days 1-5.
Urine & Fecal collection at Day -1 & days 1-5.
时间窗: at Day -1 & days 1-5.
次要结局
- Adverse events (AEs), vital signs, ECGs and clinical laboratory assessments at each day for up to 10 days(at each day for up to 10 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606Healthy SubjectsNCT00757341Wyeth is now a wholly owned subsidiary of Pfizer6
已完成
不适用
Evaluation and Validation of New Biomarkers by Mass SpectrometryDiabetes MellitusNCT01025973Université de Sherbrooke99
已完成
1 期
Investigation of Mass Balance of the Test Drug and Major MetabolitesNeoplasmsNCT00432302Bayer7
进行中（未招募）
不适用
Drug Metabolism, Excretion, and Human Body Composition of Aximus CapsulesBioequivalence TrialNCT06307132Second Affiliated Hospital of Wenzhou Medical University26
已完成
1 期
A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male ParticipantsHealthy ParticipantsNCT06309394Incyte Corporation5